|
JP2020114809A
|
|
Macular edema inhibitor
|
|
JP2020094039A
|
|
Compound with antitumor effect and production method thereof
|
|
JP2020152696A
|
|
Atg4B INHIBITOR AS NOVEL AUTOPHAGY INHIBITOR
|
|
JP2020147555A
|
|
Development of claudin-2 binding short-chain peptide having anticancer agent resistance improving action
|
|
JP2019167302A
|
|
Akr1c3 selective inhibitor and use therefor
|
|
JP2019167303A
|
|
Spinal muscular atrophy therapeutic agent
|
|
JP2019167300A
|
|
Method for producing biocompatible particle
|
|
JP2019147776A
|
|
Fluorescence probe
|
|
JP2017163933A
|
|
Screening method of pdgf-bb and related compounds in abnormal model of phosphate homeostasis
|
|
JP2017165674A
|
|
Retinoprotective action by aflibercept
|
|
WO2015108172A1
|
|
Iron(ii) ion detection agent and detection method using same
|
|
JP2015189682A
|
|
Antiviral agent
|
|
WO2014142276A1
|
|
4-hydroperoxy-trans-2-decenoic acid derivative and medicine containing same
|
|
WO2014148136A1
|
|
Compound having anti-allergic activity and use of same
|
|
JP2015020966A
|
|
Akr1c3 inhibitor
|
|
JP2014162747A
|
|
Diaminomethylene malononitrile derivative and asymmetric organic catalyst comprising the same
|
|
JP2014136172A
|
|
Method of preventing calcium elution in final disposal site
|
|
JP2014034544A
|
|
Central nerve cell plasticity promoter
|
|
JP2013193990A
|
|
Fluorescent probe
|
|
JP2013179934A
|
|
Method for screening new anticancer agent by using splicing pattern change of apoptosis promoting factor bim as index
|
